2025年12月9日之前,VolitionRx的经理和董事不得出售750万股,以避免在公开出价后出现市场波动。 Executives and directors of VolitionRx are locked out of selling 7.5 million shares until Dec. 9, 2025, to avoid market swings after a public offering.

根据2025年10月10日开始的60天封闭协议,VolitionRx有限公司的执行干事和董事在2025年12月9日之前不得出售或转让约750万股及相关证券。 Executive officers and directors of VolitionRx Limited are restricted from selling or transferring approximately 7.5 million shares and related securities until December 9, 2025, under a 60-day lock-up agreement beginning October 10, 2025. 这项限制是计划书补充书的一部分,需要新桥证券公司事先书面同意,目的是防止公开报价后市场波动。 The restriction, part of a prospectus supplement, requires prior written consent from Newbridge Securities Corporation and aims to prevent market volatility following a public offering. 该规则适用于共同股份、期权、授权证和可兑换证券,但有少数例外。 The rule applies to common shares, options, warrants, and convertible securities, with limited exceptions.